Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
NCT04484532
Completed
This pilot research trial studies the antibody response to high-dose seasonal influenza vaccination in patients with myeloid malignancy receiving chemotherapy and healthy volunteers. Evaluating antibody response to high-dose seasonal influenza vaccine may serve as a basis for vaccine recommendations in patients with myeloid malignancies and provide insights into the status of the immune system in these patients.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/02/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
NCT03739112
Completed
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/29/2023
Locations: (Site 225) Coastal Clinical Research, Mobile, Alabama +103 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Therapeutic Vaccination in Treated HIV Disease
NCT03606213
Completed
The central premise of our program is that durable control of HIV in the absence of antiretroviral therapy ("remission") will require the generation of de novo potent and sustained HIV-specific CD8+ cell responses that target evolutionarily conserved epitopes. Our program is inspired by the recent success of VGX-3100 (Inovio), a DNA therapeutic vaccine for HPV that leads to histopathologic regression of pre-malignant lesions in people and is associated with a potent, sustained boost to HPV-speci... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/26/2023
Locations: University of California, Los Angeles, Los Angeles, California +1 locations
Conditions: HIV-1-infection
Register for Updates
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
NCT04952402
Completed
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: UCLA CARE Center CRS, Los Angeles, California +5 locations
Conditions: Covid19, SARS-CoV2 Infection
Register for Updates
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713
Completed
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
05/18/2023
Locations: Eclipse Clinical Research, Tucson, Arizona +96 locations
Conditions: Pneumococcal Disease
Register for Updates
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT05589844
Withdrawn
This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic hematopoietic stem cell transplant. CMV is an opportunistic infection that can occur or reactivate after allogeneic hematopoietic stem cell transplant as a result of immunosuppression. The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules cal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
Register for Updates
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02159950
Completed
This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Tasquinimod may stop the growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether sipuleucel-T... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Register for Updates
Gene Signatures of Influenza Vaccine Responses in Older Adults
NCT03603509
Completed
The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and women. The ultimate goal is to understand how flu immunity develops after vaccination. This information may lead to the development of more effective flu vaccines in the future.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/21/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Influenza
Register for Updates
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
NCT02134184
Completed
In this study we are trying to understand whether previous infection with a particular virus, namely cytomegalovirus (CMV), influences the ability of the immune system to respond to new infections or vaccinations with age.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/17/2023
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Cytomegalovirus Infections, Influenza
Register for Updates
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
NCT05169905
Completed
The purpose of this study was to evaluate the reactogenicity, safety and immune response of a single intramuscular dose of the respiratory syncytial virus maternal (RSV MAT) vaccine in healthy non-pregnant girls 9-17 years of age (YOA) compared to non-pregnant adult women 18-49 YOA. The combined reduced-antigen-content diphtheria, tetanus and acellular pertussis (dTpa) vaccine was planned to be used as an active control for safety and reactogenicity evaluation. Following a recommendation from t... Read More
Gender:
FEMALE
Ages:
Between 9 years and 49 years
Trial Updated:
04/06/2023
Locations: GSK Investigational Site, Miami, Florida +1 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
NCT02737787
Completed
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/06/2023
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
Register for Updates
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine
NCT05750017
Unknown
This clinical trial is to study the safety and tolerability of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd. It is a phase I, randomized, double-blind, placebo-controlled, dose escalation study in healthy people aged 50 to 70 years inclusive. The study is to protect adults against shingles (herpes zoster / varicella zoster virus(VZV)). There will be about 66 participators who will receive two-dose injection at the upper arm. LZ901 vaccine is... Read More
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
03/23/2023
Locations: Frontage Clinical Services, Inc., Secaucus, New Jersey
Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Register for Updates